Skip to main content
. 2021 Dec 13;14(1):e14502. doi: 10.15252/emmm.202114502

Figure EV1. High‐throughput Screening of FDA drugs capable of inducing IL‐1β expression in M2 macrophages.

Figure EV1

  1. LPS but not IL‐4 significantly activates luciferase activity in M0 Il‐1β‐luciferase transgenic macrophages. BMDMs from Il‐1β‐luciferase transgenic mice were induced by LPS (100 ng/ml) or IL‐4 (20 ng/ml). Luciferase assays were performed 6 or 12 h after stimulation. Data are means ± SD of three independent experiments. **P < 0.01, ***P < 0.001 (Student’s t‐test).
  2. M1 or M2 markers induced in macrophages by LPS or IL‐4. BMDMs were induced by LPS (100 ng/ml) or IL‐4 (20 ng/ml) for indicated time. RT‐qPCR was then performed to quantify the expression of M1/M2 markers. Data are means ± SD of three independent experiments. ***P < 0.001 (Student’s t‐test).
  3. Carfilzomib, Bortezomib, and MLN9708 promote the expression of Il‐1β. BMDMs were pretreated by IL‐4 (20 ng/ml) for 24 h, followed by stimulation with DMSO, Carfilzomib (1 μM), Bortezomib (1 μM), or MLN9708 (2 μM) for indicated time. RNA was extracted from cells for quantification of Il‐1β expression through RT‐qPCR. Data are means ± SD of three independent experiments. ***P < 0.001 (Student’s t‐test).